422 related articles for article (PubMed ID: 23714527)
1. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.
Litzow MR
Am Soc Clin Oncol Educ Book; 2013; ():294-9. PubMed ID: 23714527
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
Hoelzer D
Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
4. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
Choudhry A; O'Brien SM
Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies in acute lymphoblastic leukemia.
Jabbour E; O'Brien S; Ravandi F; Kantarjian H
Blood; 2015 Jun; 125(26):4010-6. PubMed ID: 25999456
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
Liu D; Zhao J; Song Y; Luo X; Yang T
J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
[TBL] [Abstract][Full Text] [Related]
7. Inotuzumab Ozogamicin: First Global Approval.
Lamb YN
Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
[TBL] [Abstract][Full Text] [Related]
8. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
Jabbour E; Pui CH; Kantarjian H
JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
[TBL] [Abstract][Full Text] [Related]
9. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
Farhadfar N; Litzow MR
Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
[TBL] [Abstract][Full Text] [Related]
10. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Dahl J; Marx K; Jabbour E
Expert Rev Hematol; 2016; 9(4):329-34. PubMed ID: 26783163
[TBL] [Abstract][Full Text] [Related]
11. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
Paul S; Rausch CR; Kantarjian H; Jabbour EJ
Future Oncol; 2017 Oct; 13(25):2233-2242. PubMed ID: 28776425
[TBL] [Abstract][Full Text] [Related]
12. Antibody based therapy in relapsed acute lymphoblastic leukemia.
Jammal N; Chew S; Jabbour E; Kantarjian H
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
[TBL] [Abstract][Full Text] [Related]
13. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
[TBL] [Abstract][Full Text] [Related]
14. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Yurkiewicz IR; Muffly L; Liedtke M
Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
16. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S
Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004
[TBL] [Abstract][Full Text] [Related]
17. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Jain N; O'Brien S; Thomas D; Kantarjian H
Front Biosci (Elite Ed); 2014 Jan; 6(1):40-5. PubMed ID: 24389139
[TBL] [Abstract][Full Text] [Related]
18. Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives.
Franca R; Favretto D; Granzotto M; Decorti G; Rabusin M; Stocco G
Curr Med Chem; 2017; 24(11):1050-1065. PubMed ID: 28088906
[TBL] [Abstract][Full Text] [Related]
19. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Rubinstein JD; O'Brien MM
Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
[TBL] [Abstract][Full Text] [Related]
20. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
